Latest News - Page 45 of 49 - Oklahoma Society of Clinical Oncology

New Treatment Option for ER+/HER2

April 14, 2015 – Pfizer is sponsoring a program discussing a new treatment option for ER+/HER2 – metastatic breast cancer. This program will also be at Opus at 6:00pm. RSVPs can be registered at www.pfizerrsvphcp.com.

Read More

T-cell Lymphoma and a Treatment Option

April 9, 2015 – Celgene is sponsoring a program discussing cutaneous T-cell lymphoma and a treatment option. This program will be at Opus at 5:30pm. RSVPs can be sent to kgolden@envisioncomm.net.

Read More

LLS: Living with Myeloma Managing Side Effects and Quality of Life April 8, 2015

April 8, 2015, 12-1:30PM CST Sagar Lonial, MD, FACP, Professor and Executive Vice Chair, Department of Hematology and Medical Oncology, Chief Medical Officer, Winship Cancer Institute, Emory University School of Medicine PARTICIPATE AND LEARN MORE ABOUT: Current and emerging treatments for myeloma Monitoring disease progression Managing symptoms and treatment-related side effects Discussing quality-of-life issues with […]

Read More

LLS: NHL Update on Slow-Growing Lymphomas Telephone/Webinar

Thursday, April 16, 2015, 12-1:30 pm CST Speaker: Owen A. O’Connor, MD, PhD – Professor of Medicine and Experimental Therapeutics Director, Center for Lymphoid Malignancies, Columbia University Medical Center PARTICIPATE AND LEARN MORE ABOUT Subtypes of non-Hodgkin lymphoma Current and emerging therapies for slow-growing lymphomas Monitoring slow-growing lymphomas Managing side effects Discussing quality of life […]

Read More

NEOONS Meeting April 14, 2015

NEOONS Meeting on April 14, 2015 at 5:45pm RSVP Barbar Spaine at bspaine@cox.net or by phone at 918-519-3142. Click Here for more information.

Read More

Oklahoma Gov. Mary Fallin Signs Prescription Monitoring Bill

Last year, the Oklahoma Legislature failed to approve a bill to require doctors to check the database every time they write a prescription for these addictive drugs. Medical groups lobbied against that bill, saying its requirements would be burdensome for doctors.

Read More

OSCO’s ASCO/State Affiliate Council Representative, Shubham Pant, MD Makes Oklahoma Magazine’s 40 Under 40

Read More

Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology

ASCO provides a summary of issues and recommendations related to the 340B program for policymakers to consider from the perspective of professionals dedicated to the prevention, diagnosis and treatment of cancer.

Read More

OSCO March 28, 2015 Nurse Meeting Presentations & Pictures:

Compassion Fatigue: Caring Too Much (Peter Bjerkerot, RN) Situational Awareness (TJ Hutton and Jared Mitchell) Click Here for Meeting Photo Album

Read More

Blincyto, the first and only FDA-approved Bispecific CD19-directed CD3 T-cell Engager

Speaker: Dr. Stefan Faderl, chief Leukemia Division of Hackensack Medical Center in New Jersey 6pm, April 1, 2015 Mahogany, 3241 West Memorial Road, OKC (405-748-5859) RSVPs can be sent to Ruth Kostur at 503-412-9999 or rkostur@onyx.com. Click Here for more information

Read More